Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CellPress: Emerging Field of OV Based Cancer Immunotherapy

<< Previous

Bullboard Posts

Next >>

Comment by JohnnyYegon Oct 27, 2024 12:49am

174 Views

Post# 36283787

RE:RE:RE:RE:RE:RE:RE:CellPress: Emerging Field of OV Based Cancer Immunotherapy

In the absence of information or news, or knowledge we are left with conjecture. This news of Matt's involvement with reovirus and liver cancer makes me wonder if perhaps his leave of absence is directly related to this - perhaps it has become personal and he is taking up a direct involvement as such.

Just me surmising...

<< Previous

Bullboard Posts

Next >>

The top 10 artificial intelligence penny stocks